

L5 10640 COEXPRESS

=> s 14 and 15

L6 8 L4 AND L5

=> dup rem 16

PROCESSING COMPLETED FOR L6

L7 7 DUP REM L6 (1 DUPLICATE REMOVED)

=> d ibib abs 1-7

L7 ANSWER 1 OF 7 MEDLINE

ACCESSION NUMBER: 96360044 MEDLINE

DOCUMENT NUMBER: 96360044

TITLE: Cloning and characterization of the human **GABAA**

**receptor** alpha 4 subunit: identification of a  
unique diazepam-insensitive binding site.

AUTHOR: Yang W; Drewe J A; Lan N C

CORPORATE SOURCE: CoCensys, Inc., Irvine, CA 92718, USA.

SOURCE: EUROPEAN JOURNAL OF PHARMACOLOGY, (1995 Nov 30)

291 (3) 319-25.

Journal code: EN6. ISSN: 0014-2999.

PUB. COUNTRY: Netherlands

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199612

AB Benzodiazepines modulate gamma-aminobutyric acid (GABA)-evoked chloride currents through a specific binding site at the **GABAA receptor**-chloride channel complex. The **heterogeneity** of diazepam-sensitive benzodiazepine binding sites (type I and type II) has been identified by pharmacological approaches both with native receptors and recombinant receptors coexpressing alpha, beta and gamma subunits. In addition, two distinguishable diazepam-insensitive benzodiazepine sites are found, spatially distributed between cerebral cortical and cerebellar regions. **Coexpression** of alpha 6 with beta 2 and gamma 2L subunits creates a pharmacologically similar benzodiazepine receptor to the diazepam-insensitive site observed in cerebellum, however, there is

no evidence regarding the possible subunit combination forming the DI site  
in cerebral tissues. Here we report the cloning of the human alpha 4 cDNA  
and

its pharmacology by **coexpression** of this alpha 4 subunit with beta 2 and gamma 2L subunits. This recombinant receptor complex showed a high affinity for the previously described benzodiazepine partial agonist bretazenil, the pyrazoloquinoline compounds CGS-9895 and CGS-9896, as well as the inverse agonists DMCM (methyl 6,7-dimethoxy 4-ethyl-beta-carboline-3-carboxylate) and Ro15-4513 as determined by [3H]Ro15-4513 binding. However, it is insensitive to the benzodiazepine type I selective compounds CL218.872 (3-methyl-6-[3-(trifluoromethyl)phenyl]-1,2,4-triazolo[4.3-b]pyridazine) and zolpidem as well as the benzodiazepine full agonists diazepam, halazepam and midazolam. In addition, the benzodiazepine receptor ligands DMCM, beta-CCG

(beta-carboline-3-carboxylate ethyl ester), Beta-CCM (beta-carboline-3-carboxylate methyl ester), FG-7142, CGS-9895 and CGS-9896 showed 7 to 10 times higher affinity for alpha 4 beta 2 gamma 2L. The pharmacology of

the alpha 4 beta 2 gamma 2L receptor complex appears to resemble those of the diazepam-insensitive site found in the cerebral cortex. Our study thus suggests that this subpopulation of diazepam-insensitive GABAA receptors may be composed of alpha 4 beta 2 gamma 2L subunits.

L7 ANSWER 2 OF 7 MEDLINE

ACCESSION NUMBER: 95097362

MEDLINE

DOCUMENT NUMBER: 9509002  
TITLE: Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring **GABAA receptor** into a diazepam-preferring **GABAA receptor**  
AUTHOR: Wieland H A; Luddens H  
CORPORATE SOURCE: Laboratory for Molecular Neuroendocrinology, Center for Molecular Biology, Heidelberg, Germany..  
SOURCE: JOURNAL OF MEDICINAL CHEMISTRY, (1994 Dec 23) 37 (26) 4576-80.  
Journal code: JOF. ISSN: 0022-2623.  
PUB. COUNTRY: United States  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals; Cancer Journals  
ENTRY MONTH: 199503

AB Benzodiazepines (BZ) exert their effects through GABAA receptors, which belong to the superfamily of ligand-gated ion channels.  
**Coexpression** of recombinant alpha, beta, and gamma subunits in a cell culture system mimics the BZ binding sites. The alpha variants largely determine the nature of the BZ binding site in such alpha i beta

j gamma k **heteromultimers** (i = 1-6; j = 1-3; k = 1-3). Notably, the alpha 1 and alpha 6 variants confer high and low affinity for BZ agonists to the resulting receptor subtype, respectively.  
Glycine/glutamate and histidine/arginine positions in the alpha subunits of alpha x beta 2 gamma 2 receptors are involved in BZ I versus BZ II

type selectivity. We now identify four amino acids in alpha 6 which together increase the affinity of the mutant alpha x beta 2 gamma 2 receptor for classical BZ receptor agonists above the level seen for any wild-type GABAA/BZ receptor. The most pronounced effect was due to an isoleucine to valine exchange. It simultaneously decreased the affinity for the BZ partial inverse agonist Ro 15-4513 20-fold and increased the affinity for diazepam 4-fold. The four amino acid residues stretch over most part of the N-terminal extracellular domain of the alpha subunit, suggesting that amino acids distant in the primary sequence form the BZ binding pocket.

L7 ANSWER 3 OF 7 MEDLINE  
ACCESSION NUMBER: 93217527 MEDLINE  
DOCUMENT NUMBER: 93217527  
TITLE: Assembly of **GABAA receptor** subunits:  
alpha 1 beta 1 and alpha 1 beta 1 gamma 2S subunits  
produce unique ion channels with dissimilar single-channel properties.  
AUTHOR: Angelotti T P; Macdonald R L  
CORPORATE SOURCE: Department of Pharmacology, University of Michigan Medical School, Ann Arbor 48109-1687..  
CONTRACT NUMBER: P01 NS19163 (NINDS)  
GM 07767-14 (NIGMS)  
SOURCE: JOURNAL OF NEUROSCIENCE, (1993 Apr) 13 (4) 1429-40.  
Journal code: JDF. ISSN: 0270-6474.  
PUB. COUNTRY: United States  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199307

AB Recent experimental evidence has led to the hypothesis that **GABAA receptor** channel (GABAR) **heterogeneity** or receptor channel subtypes may occur by differential assembly of a given set of subunits into various configurations. Alternatively, assembly of subunits into mature GABARs may arise from an ordered process to produce a preferred form of the receptor channel, as seen for nicotinic ACh receptors. In the preceding article, we demonstrated that transient expression of GABAR alpha 1 and beta 1 subunits in mouse L929 fibroblast cells produced two different types of GABARs, when coexpressed with and without the gamma 2S subunit. Not only did these GABARs differ in their

GABA and diazepam pharmacology, but initial single-channel recordings suggested that the two types of GABARs (alpha 1 beta 1 and alpha 1 beta 1 gamma 2S) had different conductance and gating properties. It also appeared that alpha 1 beta 1 gamma 2S GABARs were preferentially formed over alpha 1 beta 1 GABARs, but it was not completely shown if both forms of GABARs were produced when a cell expressed all three subunits. To characterize further the assembly process and determine the preferred form, if it existed, it was necessary to obtain a kinetic "fingerprint" for both alpha 1 beta 1 and alpha 1 beta 1 gamma 2S GABARs. Thus, single-channel patch-clamp recording and kinetic analysis of receptor channel gating were performed. For both alpha 1 beta 1 and alpha 1 beta 1 gamma 2S GABARs, GABA evoked single-channel openings to both a main conductance (15 and 29 pS, respectively) and a subconductance level (10 and 21 pS, respectively) with greater than 90% of the total current through the main conductance level openings. The two GABAR populations were further differentiated by their open and burst properties. On average, alpha 1 beta 1 gamma 2S GABARs opened for almost three times the duration as alpha 1 beta 1 GABARs (6.0 vs 2.3 msec, respectively) and had three openings per burst. alpha 1 beta 1 GABARs opened predominantly as single opening bursts. Using the conductance and gating properties to differentiate the two GABAR populations, we determined that alpha 1 beta

1

GABARs were rarely, if ever, formed upon coexpression of all three subunits, suggesting that alpha 1 beta 1 gamma 2S GABARs were the preferred final form of the receptor channel. Also, the homogeneity of

the

conductance and gating properties of alpha 1 beta 1 gamma 2S GABARs among the different patches studied implied that a single preferred configuration of GABARs may exist. (ABSTRACT TRUNCATED AT 400 WORDS)

L7 ANSWER 4 OF 7

ACCESSION NUMBER: 93341494

MEDLINE

DOCUMENT NUMBER: 93341494

TITLE:

Regional gamma-aminobutyric acid sensitivity of t-butylbicyclopophosphoro[35S]thionate binding depends on gamma-aminobutyric acidA receptor alpha subunit.

AUTHOR:

Korpi E R; Luddens H

CORPORATE SOURCE:

Laboratory of Molecular Neuroendocrinology, University of Heidelberg, Germany..

SOURCE:

MOLECULAR PHARMACOLOGY, (1993 Jul) 44 (1) 87-92.

PUB. COUNTRY:

Journal code: NGR. ISSN: 0026-895X.

PUB. COUNTRY:

United States  
Journal; Article; (JOURNAL ARTICLE)

LANGUAGE:

English

FILE SEGMENT:

Priority Journals; Cancer Journals

ENTRY MONTH:

199311

AB

gamma-Aminobutyric acid (GABA) modulates the convulsant binding site on GABAA receptors labeled by t-butylbicyclopophosphoro[35S] thionate ([35S]TBPS). The modulation varies between different brain regions, reflecting the molecular heterogeneity of the GABAA receptors.

In rat brain cryostat sections, the main sensitivity difference to GABA between brain regions was observed within the cerebellum. [35S]TBPS binding in the granule cell layer was more sensitive to GABA than was

that

in the molecular layer and was detected only after blockade of the GABA agonist sites by the specific GABAA antagonists SR 95531, RU 5135, and bicuculline. This indicates that the [35S]TBPS binding sites in cerebellar

granule cells were blocked by endogenous GABA. In contrast, the internal rim of the granule cell layer had a small amount of binding that was largely insensitive to 50 microM GABA. The molecular basis for the sensitivity difference could be traced to the alpha subunits of the GABAA receptor. Expression in human embryonic kidney 293 cells of alpha 6 beta 2 gamma 2 receptors produced [35S] TBPS binding sites that were about 10-fold more sensitive to inhibition by GABA than were those inherent to alpha 1 beta 2 gamma 2 receptors.

Coexpression of alpha 6 and beta 2 subunits produced [35S]TBPS binding sites that were largely insensitive to GABA inhibition,

resembling

in their pharmacological profile the sites in the internal granule cell layer. Furthermore, the differences between alpha 6 and alpha 2 and alpha 6 beta 2 gamma 2 receptors stress the importance of the gamma 2 subunit for the proper pharmacological fingerprint of the rest of the granule cell layer. The neurosteroid 5 alpha-pregnan-3 alpha-ol-20-one affected the binding in both alpha 1 beta 2 gamma 2 and alpha 6 beta 2 gamma 2 receptors, but inhibition was greater in alpha 6-containing than in alpha 1-containing receptors, suggesting differential coupling of both GABA and neurosteroid sites with the convulsant site. These data might serve as a platform for additional studies to assess the amino acid residues in the two alpha subunits that are critically involved in the allosteric interactions between the GABAA agonist/antagonist or neurosteroid domains and the convulsant site.

- L7 ANSWER 5 OF 7 MEDLINE  
 ACCESSION NUMBER: 89181956 MEDLINE  
 DOCUMENT NUMBER: 89181956  
 TITLE: Importance of a novel GABAA receptor subunit for benzodiazepine pharmacology.  
 AUTHOR: Pritchett D B; Sontheimer H; Shivers B D; Ymer S; Kettenmann H; Schofield P R; Seeburg P H  
 CORPORATE SOURCE: ZMBH, Universitat Heidelberg, FRG..  
 SOURCE: NATURE, (1989 Apr 13) 338 (6216) 582-5.  
 PUB. COUNTRY: ENGLAND: United Kingdom  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals; Cancer Journals  
 ENTRY MONTH: 198907
- AB Neurotransmission effected by GABA (gamma-aminobutyric acid) is predominantly mediated by a gated chloride channel intrinsic to the GABAA receptor. This heterooligomeric receptor exists in most inhibitory synapses in the vertebrate central nervous system (CNS) and can be regulated by clinically important compounds such as benzodiazepines and barbiturates. The primary structures of GABAA receptor alpha- and beta-subunits have been deduced from cloned complementary DNAs. Co-expression of these subunits
- in heterologous systems generates receptors which display much of the pharmacology of their neural counterparts, including potentiation by barbiturates. Conspicuously, however, they lack binding sites for, and consistent electrophysiological responses to, benzodiazepines. We now report the isolation of a cloned cDNA encoding a new GABAA receptor subunit, termed gamma 2, which shares approximately 40% sequence identity with alpha- and beta-subunits and whose messenger RNA
- is prominently localized in neuronal subpopulations throughout the CNS. Importantly, coexpression of the gamma 2 subunit with alpha 1 and beta 1 subunits produces GABAA receptors displaying high-affinity binding for central benzodiazepine receptor ligands.
- L7 ANSWER 6 OF 7 MEDLINE  
 ACCESSION NUMBER: 90076482 MEDLINE  
 DOCUMENT NUMBER: 90076482  
 TITLE: Pharmacological characterization and region-specific expression in brain of the beta 2- and beta 3-subunits of the rat GABAA receptor.  
 AUTHOR: Lolait S J; O'Carroll A M; Kusano K; Mahan L C  
 CORPORATE SOURCE: Laboratory of Cell biology, NIMH, Bethesda, MD 20892..  
 SOURCE: FEBS LETTERS, (1989 Nov 20) 258 (1) 17-21.  
 PUB. COUNTRY: Journal code: EUH. ISSN: 0014-5793.  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals; Cancer Journals  
 ENTRY MONTH: 199003
- AB The cDNA for a third beta-subunit of the rat GABAA receptor has been cloned using another beta-subunit, which we had previously cloned [(1989) FEBS Lett. 246, 145-148], as a probe. The

approximately 8-kb cDNA for this beta-subunit (termed beta 2) encodes a protein of 474 amino acid residues that shares approximately 80% sequence identity with the rat and bovine beta 1- and beta 3-subunits.

**Coexpression** of the cloned beta-subunit cDNA with the alpha 1-subunit cDNA of the rat **GABAA receptor** in Xenopus oocytes produced a functional receptor and Cl<sup>-</sup> channel with pharmacological characteristics of a **GABAA receptor**.

In contrast to interchanging alpha-subunits [(1988) Nature 335, 76-79], exchange of beta 2- or beta 3-subunits in an alpha 1/beta receptor

complex

did not markedly alter the pharmacological properties of expressed receptors. In situ hybridization histochemistry with synthetic subunit-specific oligo-deoxynucleotide probes revealed a region-specific expression of alpha 1-, beta 2- and beta 3-subunit mRNAs in the rat central nervous system. These observations provide an additional

molecular

basis for the functional **heterogeneity** in the **GABAA receptor** complex.

L7 ANSWER 7 OF 7 MEDLINE DUPLICATE 1  
ACCESSION NUMBER: 89058643 MEDLINE  
DOCUMENT NUMBER: 89058643  
TITLE: Transient expression shows ligand gating and allosteric potentiation of **GABAA receptor** subunits.  
AUTHOR: Pritchett D B; Sontheimer H; Gorman C M; Kettenmann H; Seeburg P H; Schofield P R  
CORPORATE SOURCE: Laboratory of Molecular Neuroendocrinology, ZMBH, University of Heidelberg, Federal Republic of Germany..  
SOURCE: SCIENCE, (1988 Dec 2) 242 (4883) 1306-8.  
Journal code: UJ7. ISSN: 0036-8075.  
PUB. COUNTRY: United States  
LANGUAGE: English  
FILE SEGMENT: Priority Journals; Cancer Journals  
ENTRY MONTH: 198903  
AB Human gamma-aminobutyric acid A (**GABAA**) **receptor** subunits were expressed transiently in cultured mammalian cells. This expression system allows the simultaneous characterization of ligand-gated ion channels by electrophysiology and by pharmacology. Thus, **coexpression** of the alpha and beta subunits of the **GABAA receptor** generated GABA-gated chloride channels and binding sites for **GABAA receptor** ligands. Channels consisting of only alpha or beta subunits could also be detected. These homomeric channels formed with reduced efficiencies compared to the **heteromeric** receptors. Both of these homomeric GABA-responsive channels were potentiated by barbiturate, indicating that sites for both ligand-gating and allosteric potentiation are present on receptors assembled from either subunit.

=> s gabab

L8 3037 GABAB

=> d his

(FILE 'HOME' ENTERED AT 16:10:24 ON 19 MAY 2000)

FILE 'MEDLINE, BIOSIS, BIOTECHNO' ENTERED AT 16:10:41 ON 19 MAY 2000

L1 9581 S GABA? RECEPTOR  
L2 536512 S HETERO?  
L3 571 S L1 AND L2  
L4 415 S L3 AND PY <1998  
L5 10640 S COEXPRESSION  
L6 8 S L4 AND L5  
L7 7 DUP REM L6 (1 DUPLICATE REMOVED)

L8 3037 S GABAB

=> s gabab?

L9 3068 GABAB?

=> s 19 and 12

L10 146 L9 AND L2

=> d ibib abs 140-146

L10 ANSWER 140 OF 146 BIOSIS COPYRIGHT 2000 BIOSIS

ACCESSION NUMBER: 1990:334740 BIOSIS

DOCUMENT NUMBER: BA90:42759

TITLE: INHIBITION OF BACLOFEN BINDING TO RAT CEREBELLAR MEMBRANES BY PHACLOFEN SACLOFEN 3 AMINOPROPYLPHOSPHONIC ACID AND RELATED GABA-B RECEPTOR ANTAGONISTS.

AUTHOR(S): DREW C A; JOHNSTON G A R; KERR D I B; ONG J

CORPORATE SOURCE: DEP. PHARMACOL., UNIV. SYDNEY, SYDNEY, NSW 2006, AUST.

SOURCE: NEUROSCI LETT, (1990) 113 (1), 107-110.

CODEN: NELED5. ISSN: 0304-3940.

FILE SEGMENT: BA; OLD

LANGUAGE: English

AB The inhibition of the binding of the **GABAB** agonist

[3H](-)-baclofen to rat cerebellar membranes by some sulfonic and phosphonic acid analogues of GABA has been studied. These analogues have been shown to act as **GABAB** antagonists in the rat cortical wedge and the guinea-pig isolated ileum preparations. The order of potency of phaclofen (IC50 118 .mu.m), 2-hydroxysaclofen (IC50 5.1 .mu.M) and saclofen (IC50 7.8 .mu.M) as inhibitors of [3H](-)-baclofen binding was similar to the order of potency of these compounds as **GABAB** antagonists, whereas 3-aminopropylphosphonic acid (IC50 1.5 .mu.M) and 4-aminobutyrylphosphonic acid (IC50 3.9 .mu.M) were much more potent than anticipated from their relatively weak **GABAB** antagonist actions. These results indicate that inhibition of [3H](-)-baclofen binding to rat cerebellar membranes does not reflect antagonist activity at **GABAB** receptors seen in the rat cortical wedge preparation or the guinea-pig isolated ileum preparations. This may indicate a **heterogeneity** of **GABAB** binding and receptor sites.

L10 ANSWER 141 OF 146 BIOSIS COPYRIGHT 2000 BIOSIS

ACCESSION NUMBER: 1990:267286 BIOSIS

DOCUMENT NUMBER: BA90:9372

TITLE: SUBTYPES OF GAMMA AMINOBUTYRIC ACID RECEPTORS EXPRESSED IN XENOPUS OOCYTES INJECTED WITH GUINEA-PIG CEREBRAL

MESSANGER

RNA.

AUTHOR(S): SEKIGUCHI M; OKAMOTO K; SAKAI Y

CORPORATE SOURCE: DEP. OF PHARMACOL., NATL. DEFENSE MED. COLL., TOKOROZAWA SAITAMA 359, JAPAN.

SOURCE: J NATL DEF MED COLL., (1989) 14 (4), 218-226.

CODEN: BIDZDQ. ISSN: 0385-1796.

FILE SEGMENT: BA; OLD

LANGUAGE: Japanese

AB For the purpose of investigating the subtypes of receptors for .gamma.-aminobutyric acid (GABA, a major inhibitory neurotransmitter in mammalian central nervous systems), the mRNA extracted from the guinea

pig

cerebrum was injected into Xenopus laevis oocytes, and expressed GABA receptors were electrophysiologically and pharmacologically studied using a voltage-clamp technique. As a result, it was found that two types of GABA receptors were expressed in Xenopus oocytes, one was the GABAA receptor which was sensitive to picrotoxinin (a chloride channel blocker) and insensitive to phaclofen (a specific antagonist of the **GABAB** receptor), and the other was the picrotoxinin-insensitive and phaclofen-sensitive **GABAB** receptor. Furthermore, it was also found that the responses of mRNA-injected oocytes to GABA were antagonized

by bicuculline (a competitive antagonist specific to the GABAA receptor) in some oocytes, while bicuculline functioned as a more potent agonist than GABA in other oocytes. This finding suggests that there is **heterogeneity** in the GABAA receptors expressed in Xenopus oocytes by injection of guinea pig cerebral mRNA.

L10 ANSWER 142 OF 146 BIOSIS COPYRIGHT 2000 BIOSIS

ACCESSION NUMBER: 1990:158300 BIOSIS

DOCUMENT NUMBER: BA89:85718

TITLE: DIFFERING ACTIONS OF BACLOFEN AND 3 AMINOPROPYLPHOSPHINIC ACID IN RAT NEOCORTICAL SLICES.

AUTHOR(S): ONG J; KERR D I B; JOHNSTON G A R; HALL R G

CORPORATE SOURCE: DEP. ANAESTHESIA INTENSIVE CARE, UNIV. ADELAIDE, ADELAIDE, S.A. 5000, AUSTRALIA.

SOURCE: NEUROSCI LETT, (1990) 109 (1-2), 169-173.

CODEN: NELED5. ISSN: 0304-3940.

FILE SEGMENT: BA; OLD

LANGUAGE: English

AB Rat neocortical slices maintained in Mg2+-free Krebs medium developed spontaneous paroxysmal discharges which were attenuated or suppressed by the gamma-aminobutyric acid-B (GABAB) receptor agonist baclofen, occasionally accompanied by a slight hyperpolarisation, and antagonised by the specific GABAB-receptor antagonist, 2-OH-salcofen. Over the same dose range, the GABA-analogue 3-amino-propylphosphinic acid (3-APA) caused a marked, prompt hyperpolarisation with little or no effect on the frequency of the discharges, although their amplitude was attenuated. In the presence of 2-OH-salcofen, 3-APA still induced a hyperpolarisation but the amplitude of the discharges was no longer affected. This marked differences in action between baclofen

and

3-APA in the rat neocortical slices suggests there may be a **heterogeneity** of GABAB-receptors.

L10 ANSWER 143 OF 146 BIOSIS COPYRIGHT 2000 BIOSIS

ACCESSION NUMBER: 1989:97129 BIOSIS

DOCUMENT NUMBER: BA87:51265

TITLE: POSTSYNAPTIC POTENTIALS RECORDED IN NEURONS OF THE CAT'S LATERAL GENICULATE NUCLEUS FOLLOWING ELECTRICAL

STIMULATION

OF THE OPTIC CHIASM.

AUTHOR(S): BLOOMFIELD S A; SHERMAN S M

CORPORATE SOURCE: DEP. OPHTHALMOL., NEW YORK UNIV. MED. CENT., 550 FIRST AVE,

NEW YORK, N.Y. 10016.

SOURCE: J NEUROPHYSIOL (BETHESDA), (1988) 60 (6), 1924-1945.

CODEN: JONEA4. ISSN: 0022-3077.

FILE SEGMENT: BA; OLD

LANGUAGE: English

AB We recorded intracellularly from X and Y cells of the cat's lateral geniculate nucleus and measured the postsynaptic potentials (PSPs) evoked from electrical stimulation of the optic chiasm. We used an in vivo preparation and computer averaged the PSPs to enhance their signal-to-noise ratio. The vast majority (46 of 50) of our sample of X

and

Y cells responded to stimulation of the optic chiasm with an excitatory postsynaptic potential (EPSP) followed by an inhibitory postsynaptic potential (IPSP); these were tentatively identified as relay cells. We quantified several parameters of these PSPs, including amplitude,

latency,

time to peak (i.e., rise time), and duration. Among the relay cells, the latencies of both the EPSP and action potential evoked by optic chiasm stimulation were shorter in Y cells than in X cells. Furthermore, the difference between the latencies of the EPSP and action potential was shorter for Y cells than for X cells. This means that the EPSPs generated in Y cells reached threshold for generation of action potentials faster than did those in X cells. The EPSPs of Y cells also displayed larger amplitudes and faster rise times than did those in X cells, but neither

of

these distinctions was sufficient to explain the shorter latency

difference between EPSP and action potential for cells. The EPSPs recorded in relay Y cells had longer durations than those in relay X cells. Our data suggest that the subsequent IPSP actively terminates the EPSP, which, in turn, suggests that the time interval between EPSP and IPSP onsets is longer in Y cells than in X cells. Furthermore, we found that, for individual Y cells, the latency and duration of the evoked EPSP were inversely related. These observations lead to the conclusion that the latency of IPSPs activated from the optic chiasm is relatively constant among Y cells and thus independent of the EPSP latencies. Thus the excitation and inhibition produced in individual geniculate Y cells may originate from different populations of retinogeniculate axons. The IPSPs recorded in geniculate relay cells following optic chiasm stimulation could be divided into three groups based on their durations. The majority of both X and Y cells showed short-duration IPSPs, whereas the remainder of Y cells displayed medium-duration IPSPs, and the remaining X cells displayed long-duration IPSPs. A positive correlation was seen between time to peak and duration of these IPSPs. The reversal potential of short duration IPSPs, for both X and Y cells, was about -76 mV. In contrast, reversal potentials of both medium- and long-duration IPSPs were about -102 mV. These data suggest that, in response to optic chiasm stimulation, both X and Y cells display two types of inhibition that differ in their ionic conductances. We found no evidence that any of the relay cells produced an IPSP. Given prior evidence that gamma-aminobutyric acid (GABA) is the dominant inhibitory neurotransmitter in the lateral geniculate nucleus, we propose that short-duration IPSPs reflect a chloride conductance that may be mediated by a GAGAA receptor, whereas medium- and long-duration IPSPs may each reflect a potassium conductance mediated by GABAB receptors. We found that the standard deviations for 8 of 10 PSP parameters were greater for relay X cells than for relay Y cells. This finding extends to PSPs a previous assertion, based on other morphological and physiological data, that the C cell population is more heterogeneous than is the Y cell population. We recorded from four neurons, all X cells, that did not display any obvious IPSP following stimulation of the optic chiasm. These cells could not be driven antidromically with electrical stimulation of the visual cortex. They have thus been tentatively identified as interneurons. In addition, the evoked EPSPs in these cells were roughly 10 times longer in duration than those generated in the relay cells. However, the other tested response properties of these neurons, which included an evaluation of their receptive field properties, were indistinguishable from those of relay X cells.

L10 ANSWER 144 OF 146 BIOSIS COPYRIGHT 2000 BIOSIS

ACCESSION NUMBER: 1987:254345 BIOSIS

DOCUMENT NUMBER: BA84:7317

TITLE: GABA-A AND GABA-B RECEPTOR SITE DISTRIBUTION IN THE RAT CENTRAL NERVOUS SYSTEM.

AUTHOR(S): BOWERY N G; HUDSON A L; PRICE G W

CORPORATE SOURCE: MERCK SHARP AND DOHME RES. LAB., NEUROSCI. RES. CENT., TERLINGS PARK, EASTWICK RD., HARLOW, ESSEX CM20 2QR, UK.

SOURCE: NEUROSCIENCE, (1987) 20 (2), 365-384.

CODEN: NRSCDN. ISSN: 0306-4522.

FILE SEGMENT: BA; OLD

LANGUAGE: English

AB An autoradiographic procedure has been used to determine the quantitative distributions of gamma-aminobutyric acid (GABAA and GABAB) receptor subtypes in rat brain. Although the concentrations of both receptor binding sites were similar in some brain regions GABAA sites generally outnumbered GABAB sites. The highest concentration of GABAA sites were detected in the frontal cortex, the granule cell layer

of the cerebellum, the olfactory bulb and the thalamic medial geniculate.

The highest concentration of GABAB sites occurred in the molecular layer of the cerebellum, the interpeduncular nucleus, frontal cortex,



anterior olfactory nucleus and thalamic nuclei. In addition the globus pallidus, temporal cortex, lateral posterior thalamus, superior colliculus, pontine nucleus, raphe magnus, spinal trigeminal tract and substantia gelatinosa contained significantly more GABAB sites than GABAA sites. The physiological and pharmacological significance of this heterogeneity has yet to be determined.

L10 ANSWER 145 OF 146 BIOSIS COPYRIGHT 2000 BIOSIS

ACCESSION NUMBER: 1986:164205 BIOSIS

DOCUMENT NUMBER: BA81:74621

TITLE: EVIDENCE FOR GAMMA AMINOBUTYRIC-ACID AUTORECEPTORS IN MEDIAN EMINENCE.

AUTHOR(S): ANDERSON R A; MITCHELL R

CORPORATE SOURCE: MRC BRAIN METABOLISM UNIT, DEP. PHARMACOL., 1 GEORGE SQUARE, EDINBURGH EH8 9JZ, SCOTLAND.

SOURCE: EUR J PHARMACOL, (1985) 118 (3), 355-358.

CODEN: EJPHAZ. ISSN: 0014-2999.

FILE SEGMENT: BA; OLD

LANGUAGE: English

AB The effect of the selective GABAB receptor agonist baclofen was examined on stimulus-induced release of [3H]GABA from crude synaptosomal preparations of median eminence (ME) and pituitary neurointermediate lobe (NI). Baclofen stereospecifically inhibited release of [3H]GABA in a concentration-dependent manner from ME but had no effect in NI. The

effect of (+/-) baclofen was partly antagonized by the putative GABAB receptor antagonist .delta.-aminovaleic acid, but these experiments were complicated by a degree of heteroexchange. These results provide the first evidence for GABAB autoreceptors in the CNS.

L10 ANSWER 146 OF 146 BIOSIS COPYRIGHT 2000 BIOSIS

ACCESSION NUMBER: 1986:111998 BIOSIS

DOCUMENT NUMBER: BA81:22414

TITLE: THE REGULATION OF NORADRENALINE SYNTHESIS IN CENTRAL NERVE TERMINALS BY AUTORECEPTORS AND HETERORECEPTORS IN RAT.

AUTHOR(S): BIRCH P J; FILLENZ M

CORPORATE SOURCE: UNIV. LAB. PHYSIOLOGY, PARKS ROAD, OXFORD OX1 3PT, U.K.

SOURCE: NEUROSCI LETT, (1985) 59 (2), 197-202.

CODEN: NELEDS. ISSN: 0304-3940.

FILE SEGMENT: BA; OLD

LANGUAGE: English

AB The effects of .alpha.2-adrenoceptor and .gamma.-aminobutyric acidB (GABAB) receptor activation on noradrenaline synthesis were measured in rat hippocampal synaptosomes. The results show that .alpha.2-autoreceptors and GABAB heteroreceptors inhibit K+-accelerated synthesis; they have no effect on basal synthesis.

=> d his

(FILE 'HOME' ENTERED AT 16:10:24 ON 19 MAY 2000)

FILE 'MEDLINE, BIOSIS, BIOTECHNO' ENTERED AT 16:10:41 ON 19 MAY 2000

L1 9581 S GABA? RECEPTOR

L2 536512 S HETERO?

L3 571 S L1 AND L2

L4 415 S L3 AND PY <1998

L5 10640 S COEXPRESSION

L6 8 S L4 AND L5

L7 7 DUP REM L6 (1 DUPLICATE REMOVED)

L8 3037 S GABAB

L9 3068 S GABAB?

L10 146 S L9 AND L2

=> s dimer or dimeric or heterodimer or heterodimeric

L11 75555 DIMER OR DIMERIC OR HETERODIMER OR HETERODIMERIC

=> s 111 and 19

L12 8 L11 AND L9

=> dup rem 112

PROCESSING COMPLETED FOR L12

L13 6 DUP REM L12 (2 DUPLICATES REMOVED)

=> d ibib abs 1-6

L13 ANSWER 1 OF 6 BIOSIS COPYRIGHT 2000 BIOSIS

ACCESSION NUMBER: 2000:109727 BIOSIS

DOCUMENT NUMBER: PREV200000109727

TITLE: gamma-Aminobutyric acidB receptors: First of the functional

metabotropic heterodimers.

AUTHOR(S): Bowery, Norman G. (1); Enna, S. J.

CORPORATE SOURCE: (1) Medical School, Department of Pharmacology, University of Birmingham, Edgbaston, Birmingham, B15 2TT UK

SOURCE: Journal of Pharmacology and Experimental Therapeutics,

(Jan., 2000) Vol. 292, No. 1, pp. 2-7.

ISSN: 0022-3565.

DOCUMENT TYPE: Article

LANGUAGE: English

SUMMARY LANGUAGE: English

AB Activation of the metabotropic gamma-aminobutyric acidB (GABAB) receptor increases K<sup>+</sup> conductance and decreases Ca<sup>2+</sup> channel activity in neuronal membranes. Studies with a number of new GABAB receptor agonists and antagonists reveal that in addition to their muscle relaxant effects, agonists display analgesic activity and reduce the craving for cocaine. With regard to GABAB receptor antagonists, preclinical data suggest they improve cognitive performance and possess

antidepressant

and antiepileptic potential. With a high-affinity GABAB antagonist, the structural properties of the receptor were characterized through expression cloning. Moreover, it has been found that expression

of

a fully functional GABAB receptor requires coupling between two separate and distinct gene products: GABAB R1 and GABAB R2. Besides being the first example of a functional heterodimeric metabotropic receptor, the components and molecular configuration of the GABAB receptor suggest novel mechanisms for producing pharmacologically distinct subtypes of G protein-coupled receptors.

L13 ANSWER 2 OF 6 BIOSIS COPYRIGHT 2000 BIOSIS

ACCESSION NUMBER: 1999:482190 BIOSIS

DOCUMENT NUMBER: PREV199900482190

TITLE: gamma-aminobutyric acid type B receptor splice variant proteins GBR1a and GBR1b are both associated with GBR2 in situ and display differential regional and subcellular distribution.

AUTHOR(S): Benke, Dietmar (1); Honer, Michael; Michel, Claudia; Bettler, Bernhard; Mohler, Hanns

CORPORATE SOURCE: (1) Institute of Pharmacology, ETH and University of Zurich, Winterthurerstrasse 190, CH-8057, Zurich Switzerland

SOURCE: Journal of Biological Chemistry, (Sept. 17, 1999) Vol. 274,

No. 38, pp. 27323-27330.

ISSN: 0021-9258.

DOCUMENT TYPE: Article

LANGUAGE: English

SUMMARY LANGUAGE: English

AB The subunit architecture of gamma-aminobutyric acid, type B (GABAB), receptors in situ is largely unknown. The GABAB receptor variants, characterized by the constituents GBR1a and GBR1b, were

therefore analyzed with regard to their subunit composition as well as their regional and subcellular distribution in situ. The analysis was based on the use of antisera recognizing selectively GBR1a, GBR1b, and GBR2. Following their solubilization, GBR1a and GBR1b were both found by immunoprecipitation to occur as heterodimers associated with GBR2. Furthermore, monomers of GBR1a, GBR1b, or GBR2 were not detectable, suggesting that practically all GABAB receptors are heterodimers in situ. Finally, there was no evidence for an association of GBR1a with GBR1b indicating that these two constituents represent two different receptor populations. A size determination of solubilized GABAB receptors by sucrose density centrifugation revealed two distinct peaks of which one corresponded to dimeric receptors, and the higher molecular weight peak pointed to the presence of yet unknown receptor-associated proteins. The distribution and relative abundance of GBR2 immunoreactivity corresponded in all brain regions to that of the sum of GBR1a and GBR1b, supporting the view that most if not all GBR1 proteins are associated with GBR2. However, GBR1a was present preferentially at postsynaptic densities, whereas GBR1b may be mainly attributed to presynaptic or extrasynaptic sites. Thus, GBR1a and GBR1b are both associated with GBR2 to form heterodimers at mainly different subcellular locations where they are expected to subserve different functions.

L13 ANSWER 3 OF 6 MEDLINE  
 ACCESSION NUMBER: 199459274 MEDLINE  
 DOCUMENT NUMBER: 99459274  
 TITLE: Heterodimerization of a functional GABAB receptor is mediated by parallel coiled-coil alpha-helices.  
 AUTHOR: Kammerer R A; Frank S; Schulthess T; Landwehr R; Lustig A; Engel J  
 CORPORATE SOURCE: Department of Biophysical Chemistry, Biozentrum, University of Basel, Switzerland.  
 SOURCE: BIOCHEMISTRY, (1999 Oct 5) 38 (40) 13263-9.  
 Journal code: AOG. ISSN: 0006-2960.  
 PUB. COUNTRY: United States  
 Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 200001  
 ENTRY WEEK: 20000104  
 AB A detailed understanding of GABAB receptor assembly is an important issue in view of its role as attractive target for treatment of epilepsy, anxiety, depression, cognitive defects, and nociceptive disorders. Heteromerization of GABAB-R1 and GABAB-R2 subunits is a prerequisite for the formation of a functional GABAB receptor. Each individual subunit contains one stretch of approximately 30 amino acid residues within its intracellular C-terminal domain that mediates heteromer formation. To investigate the mechanism of the GABAB-R1/GABAB-R2 interaction and to assess the subunit stoichiometry of the complex, recombinant polypeptide chain fragments containing the heteromerization site were produced by heterologous gene expression in Escherichia coli. When mixed in equimolar amounts, these peptides preferentially formed parallel coiled-coil heterodimers under physiological buffer conditions. This demonstrates that the short C-terminal regions are sufficient to determine the specificity of interaction between GABAB receptor subunits. In contrast, isolated GABAB-R1 peptides folded into relatively unstable homodimers, whereas GABAB-R2 peptides were largely unstructured. Together with the data reported in the literature, the results presented here indicate that the functional GABAB receptor is a heterodimer assembled by parallel coiled-coil alpha-helices.

L13 ANSWER 4 OF 6 MEDLINE  
 ACCESSION NUMBER: 2000052363 MEDLINE  
 DOCUMENT NUMBER: 20052363  
 DUPLICATE 1

TITLE: Calc sensing properties of the GABA<sub>B</sub> receptor.  
 AUTHOR: Wise Green A; Main M J; Wilson R; Lüscher N; Marshall F  
 H  
 CORPORATE SOURCE: Receptor Systems, Molecular Pharmacology Unit, Glaxo  
 Wellcome Medicines Research Centre, Stevenage,  
 Hertfordshire, UK.  
 SOURCE: NEUROPHARMACOLOGY, (1999 Nov) 38 (11) 1647-56.  
 Journal code: NZB. ISSN: 0028-3908.  
 PUB. COUNTRY: ENGLAND: United Kingdom  
 Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 200002  
 ENTRY WEEK: 20000204

AB The GABA(B) receptor has been shown to consist of a **heterodimer**  
 of two related 7-transmembrane receptors **GABAB-R1** and  
**GABAB-R2**. These receptors share close homology to the Ca<sup>2+</sup>-sensing  
 receptor and also to the metabotropic glutamate receptors, which have

also

been shown to respond to extracellular calcium. We show here that the  
 GABA(B) receptor also has Ca<sup>2+</sup> sensing properties. Ca<sup>2+</sup> (0.001-1 mM)  
 potentiated the GABA stimulation of [35S]GTPgammaS binding in membranes  
 prepared from CHO cells stably expressing the GABA(B)-R1/R2  
**heterodimer**. The GABA EC<sub>50</sub> was reduced from 72 to 7.7 microM by  
 addition of 1 mM Ca<sup>2+</sup>, with no change in the maximum response. A similar  
 effect was observed in membranes from rat brain cortex. Ca<sup>2+</sup> also  
 potentiated GABA inhibition of forskolin-stimulated cAMP levels in the

CHO

cells and enhanced coupling to GIRK K<sup>+</sup> channels in Xenopus oocytes. Other  
 divalent cations were ineffective. The effects of Ca<sup>2+</sup> were found to be  
 agonist dependent with baclofen having a reduced sensitivity compared to  
 GABA. Calcium appears to act allosterically to enhance GABA responses at  
 the GABA(B) receptor, however, unlike the Ca<sup>2+</sup>-sensing receptor and some  
 of the mGluR family, Ca<sup>2+</sup> does not act as a ligand in its own right.

L13 ANSWER 5 OF 6 MEDLINE DUPLICATE 2  
 ACCESSION NUMBER: 2000069022 MEDLINE  
 DOCUMENT NUMBER: 20069022  
 TITLE: Functional pharmacology of cloned **heterodimeric**  
**GABAB** receptors expressed in mammalian cells.

AUTHOR: Brauner-Osborne H; Krosgaard-Larsen P  
 CORPORATE SOURCE: NeuroScience PharmaBiotec Centre, Department of Medicinal  
 Chemistry, The Royal Danish School of Pharmacy,  
 Universitetsparken 2, DK-2100 Copenhagen, Denmark..  
 hans@medchem.dfh.dk  
 SOURCE: BRITISH JOURNAL OF PHARMACOLOGY, (1999 Dec) 128 (7)  
 1370-4.

JOURNAL CODE: B00. ISSN: 0007-1188.  
 PUB. COUNTRY: ENGLAND: United Kingdom  
 Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 200004  
 ENTRY WEEK: 20000401

AB 1. In this study we report a new assay of **heterodimeric**  
 gamma-amino-butyric acid subtype B (**GABAB**) receptors where  
 either **GABABR1a** or **GABABR1b** are co-expressed with  
**GABABR2** and the chimeric G-protein Galphaz5 in tsA cells. In  
 this manner we obtained a robust response to **GABAB** agonists  
 measured as increase in phosphoinositide hydrolysis. 2. We used this  
 assay  
 to characterize a number of commonly used **GABAB** receptor  
 ligands. Both splice variants displayed the same rank order of agonist  
 potency; 3-aminopropyl(methyl)phosphinic acid  
 ((SKF-97541)>**GABA**)>(R)-4-amino-  
 3-(4-chlorophenyl)butanoic acid  
 ((R)-baclofen)>(RS)-4-amino-3-(5-chloro-2-  
 thienyl)butanoic acid (BCTG)>3-aminopropylphosphonic acid (3-APPA) and  
 furthermore, the absolute agonist potency values were very close to each

other. 3. 3-APPA was a partial agonist displaying maximal responses of 41 and 61% compared to GABA at **GABAB1a** and **GABAB1b**, respectively. The antagonist (RS)-3-amino-2-(4-chlorophenyl)-2-hydroxypropylsulphonic acid (2-OH-saclofen) displayed KB values of 15 and 7.8  $\mu\text{M}$  at **GABAB1a** and **GABAB1b**, respectively. 4. The rank order of agonist potency as well as the absolute ligand potencies correspond very well with those previously reported in different tissues, and this study thus provides a functional assay of cloned **GABAB** receptors which should be a valuable tool for further characterization of **GABAB** ligands. Finally, we can conclude that the functional pharmacological profiles of the two **GABAB1** splice variants are very similar.

L13 ANSWER 6 OF 6 BIOSIS COPYRIGHT 2000 BIOSIS  
 ACCESSION NUMBER: 2000:33120 BIOSIS  
 DOCUMENT NUMBER: PREV200000033120  
 TITLE: **GABAB** receptors - the first 7TM heterodimers.  
 AUTHOR(S): Marshall, Fiona H. (1); Jones, Kenneth A.; Kaupmann, Klemens; Bettler, Bernhard  
 CORPORATE SOURCE: (1) Receptor Systems, Molecular Pharmacology Unit, Glaxo Wellcome Medicines Research Centre, Gunnels Wood Road, Stevenage, SG1 2NY UK  
 SOURCE: Trends in Pharmacological Sciences, (Oct., 1999) Vol. 20, No. 10, pp. 396-399.  
 ISSN: 0165-6147.  
 DOCUMENT TYPE: Article  
 LANGUAGE: English

=> s heterodimer?

L14 26750 HETERODIMER?

=> d his

(FILE 'HOME' ENTERED AT 16:10:24 ON 19 MAY 2000)

FILE 'MEDLINE, BIOSIS, BIOTECHNO' ENTERED AT 16:10:41 ON 19 MAY 2000  
 L1 9581 S GABA? RECEPTOR  
 L2 536512 S HETERO?  
 L3 571 S L1 AND L2  
 L4 415 S L3 AND PY <1998  
 L5 10640 S COEXPRESSION  
 L6 8 S L4 AND L5  
 L7 7 DUP REM L6 (1 DUPLICATE REMOVED)  
 L8 3037 S GABAB  
 L9 3068 S GABAB?  
 L10 146 S L9 AND L2  
 L11 75555 S DIMER OR DIMERIC OR HETERODIMER OR HETERODIMERIC  
 L12 8 S L11 AND L9  
 L13 6 DUP REM L12 (2 DUPLICATES REMOVED)  
 L14 26750 S HETERODIMER?

=> s l14 and l9

L15 15 L14 AND L9

=> s l15 not l12

L16 7 L15 NOT L12

=> dup rem l16

PROCESSING COMPLETED FOR L16  
 L17 6 DUP REM L16 (1 DUPLICATE REMOVED)

=> d ibib abs 1-6

L17 ANSWER 1 OF 6 BIOSIS COPYRIGHT 2000 BIOSIS  
 ACCESSION NUMBER: 1999:484302 BIOSIS  
 DOCUMENT NUMBER: PREV199900484302  
 TITLE: **GABAB** receptors function as **heterodimers**  
 AUTHOR(S): Marshall, F. H. (1); White, J. (1); Main, M. (1); Green, A.  
 (1); Wise, A. (1)  
 CORPORATE SOURCE: (1) Receptor Systems, Molecular Pharmacology Unit,  
 GlaxoWellcome Medicines Research Centre, Gunnels Wood  
 Road,  
 Stevenage, Hertfordshire, SG1 2NY UK  
 SOURCE: Biochemical Society Transactions, (Aug., 1999) Vol. 27,  
 No. 4, pp. 530-535.  
 Meeting Info.: 668th Meeting of the Biochemical Society  
 Glasgow, Scotland, UK April 7-9, 1999 Biochemical Society  
 . ISSN: 0300-5127.  
 DOCUMENT TYPE: Conference  
 LANGUAGE: English

L17 ANSWER 2 OF 6 MEDLINE  
 ACCESSION NUMBER: 1999429981 MEDLINE  
 DOCUMENT NUMBER: 99429981  
 TITLE: **GABAB** receptors - the first 7TM  
**heterodimers**.  
 AUTHOR: Marshall F H; Jones K A; Kaupmann K; Bettler B  
 CORPORATE SOURCE: Receptor Systems, Molecular Pharmacology Unit, Glaxo  
 Wellcome Medicines Research Centre, Gunnels Wood Road,  
 Stevenage, UK SG1 2NY.. fhm273758GlaxoWellcome.co.uk  
 SOURCE: TRENDS IN PHARMACOLOGICAL SCIENCES, (1999 Oct) 20 (10)  
 396-9. Ref: 26  
 Journal code: WFT. ISSN: 0165-6147.  
 PUB. COUNTRY: ENGLAND: United Kingdom  
 Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LANGUAGE: English  
 ENTRY MONTH: 200001  
 ENTRY WEEK: 20000104

L17 ANSWER 3 OF 6 BIOSIS COPYRIGHT 2000 BIOSIS  
 ACCESSION NUMBER: 1999:357020 BIOSIS  
 DOCUMENT NUMBER: PREV199900357020  
 TITLE: **Heterodimerisation of GABAB** receptors.  
 AUTHOR(S): Marshall, Fiona H. (1); White, Julia H. (1); Wise, Alan  
 (1); Main, Martin J. (1); Green, Andrew (1); Fraser, Neil  
 J. (1); Disney, Graham H. (1); Barnes, Ashley A. (1);  
 Foord, Steven M. (1)  
 CORPORATE SOURCE: (1) Receptor Systems, Molecular Pharmacology Unit,  
 Medicines Research Centre, Glaxo Wellcome, Gunnels Wood  
 Road, Stevenage, Hertfordshire, SG1 2NY UK  
 SOURCE: Biochemical Society Transactions, (1999) Vol. 27, No. 3,  
 pp. A70.  
 Meeting Info.: 668th Meeting of the Biochemical Society  
 Glasgow, Scotland, UK April 7-9, 1999 Biochemical Society  
 . ISSN: 0300-5127.  
 DOCUMENT TYPE: Conference  
 LANGUAGE: English

L17 ANSWER 4 OF 6 BIOSIS COPYRIGHT 2000 BIOSIS  
 ACCESSION NUMBER: 1999:57890 BIOSIS  
 DOCUMENT NUMBER: PREV199900057890  
 TITLE: **GABAB**-receptor subtypes assemble into functional  
 heteromeric complexes.  
 AUTHOR(S): Kaupmann, Klemens; Malitschek, Barbara; Schuler, Valerie;  
 Heid, Jakob; Froestl, Wolfgang; Beck, Pascal; Mosbacher,

Ryuichi; Johans; Bischoff, Serge; Kulik, Ako Shigemoto,  
 Karschin, Andreas; Bettler, Bernhard (1)  
 CORPORATE SOURCE: (1) Novartis Pharma AG, TA Nervous Syst., CH-4002 Basel  
 Switzerland  
 SOURCE: Nature (London), (Dec. 17, 1998) Vol. 396, No. 6712, pp.  
 683-687.  
 ISSN: 0028-0836.  
 DOCUMENT TYPE: Article  
 LANGUAGE: English  
 AB B-type receptors for the neurotransmitter GABA (gamma-aminobutyric acid) inhibit neuronal activity through G-protein-coupled second-messenger systems, which regulate the release of neurotransmitters and the activity of ion channels and adenylyl cyclase. Physiological and biochemical studies show that there are differences in drug efficiencies at different GABAB receptors, so it is expected that GABAB-receptor (GABABR) subtypes exist. Two GABAB-receptor splice variants have been cloned (GABABR1a and GABABR1b), but native GABAB receptors and recombinant receptors showed unexplained differences in agonist-binding potencies. Moreover, the activation of presumed effector ion channels in heterologous cells expressing the recombinant receptors proved difficult. Here we describe a new GABAB receptor subtype, GABABR2, which does not bind available GABAB antagonists with measurable potency. GABABR1a, GABABR1b and GABABR2 alone do not activate Kir3-type potassium channels efficiently, but co-expression of these receptors yields a robust coupling to activation of Kir3 channels. We provide evidence for the assembly of heteromeric GABAB receptors in vivo and show that GABABR2 and GABABR1a/b proteins immunoprecipitate and localize together at dendritic spines. The heteromeric receptor complexes exhibit a significant increase in agonist- and partial-agonist-binding potencies as compared with individual receptors and probably represent the predominant native GABAB receptor. Heteromeric assembly among G-protein-coupled receptors has not, to our knowledge, been described before.

L17 ANSWER 5 OF 6 MEDLINE DUPLICATE 1  
 ACCESSION NUMBER: 1999087321 MEDLINE  
 DOCUMENT NUMBER: 99087321  
 TITLE: Heterodimerization is required for the formation of a functional GABA(B) receptor [see comments].  
 COMMENT: Comment in: Nature 1998 Dec 17;396(6712):629-30  
 AUTHOR: White J H; Wise A; Main M J; Green A; Fraser N J; Disney G H; Barnes A A; Emson P; Foord S M; Marshall F H  
 CORPORATE SOURCE: Receptor Systems, Molecular Pharmacology Unit, GlaxoWellcome, Medicines Research Centre, Stevenage, Hertfordshire, UK.  
 SOURCE: NATURE, (1998 Dec 17) 396 (6712) 679-82.  
 Journal code: NSC. ISSN: 0028-0836.  
 PUB. COUNTRY: ENGLAND: United Kingdom  
 Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Cancer Journals; Priority Journals  
 OTHER SOURCE: GENBANK-AJ012185; GENBANK-AJ012186; GENBANK-AJ012188  
 ENTRY MONTH: 199903  
 AB GABA (gamma-aminobutyric acid) is the main inhibitory neurotransmitter in the mammalian central nervous system, where it exerts its effects through ionotropic (GABA(A/C)) receptors to produce fast synaptic inhibition and metabotropic (GABA(B)) receptors to produce slow, prolonged inhibitory signals. The gene encoding a GABA(B) receptor (GABA(B)R1) has been cloned;  
 however, when expressed in mammalian cells this receptor is retained as an immature glycoprotein on intracellular membranes and exhibits low affinity for agonists compared with the endogenous receptor on brain membranes. Here we report the cloning of a complementary DNA encoding a new subtype of the GABAB receptor (GABA(B)R2), which we identified by mining expressed-sequence-tag databases. Yeast two-hybrid screening showed that

this new GABA(B)R2-receptor subtype forms **heterodimers** with GABA(B)R1 through an interaction at their intracellular carboxy-terminal tails. Upon expression with GABA(B)R2 in HEK293T cells, GABA(B)R1 is terminally glycosylated and expressed at the cell surface. Co-expression of the two receptors produces a fully functional GABA(B) receptor at the cell surface; this receptor binds GABA with a high affinity equivalent to that of the endogenous brain receptor. These results indicate that, in vivo, functional brain GABA(B) receptors may be **heterodimers** composed of GABA(B)R1 and GABA(B)R2.

L17 ANSWER 6 OF 6 BIOSIS COPYRIGHT 2000 BIOSIS

ACCESSION NUMBER: 1999:57888 BIOSIS

DOCUMENT NUMBER: PREV199900057888

TITLE: **GABAB** receptors function as a heteromeric assembly of the subunits **GABABR1** and **GABABR2**.

AUTHOR(S): Jones, Kenneth A. (1); Borowsky, Beth; Tamm, Joe A.; Craig,

Douglas A.; Durkin, Margaret M.; Dai, Meng; Yao, Wen-Jeng; Johnson, Mary; Gunwaldsen, Caryn; Huang, Ling-Yan; Tang, Cheng; Shen, Quanrong; Salon, John A.; Morse, Kelley; Laz, Thomas; Smith, Kelli E.; Nagarathnam, Dhanapalan; Noble, Stewart A.; Branchek, Theresa A.; Gerald, Christophe (1) Synaptic Pharmaceutical Corp., 215 College Road, Paramus, NJ 07652 USA

CORPORATE SOURCE: Nature (London), (Dec. 17, 1998) Vol. 396, No. 6712, pp. 674-679.

SOURCE: ISSN: 0028-0836.

DOCUMENT TYPE: Article

LANGUAGE: English

AB The principal inhibitory neurotransmitter GABA (gamma-aminobutyric acid) exerts its effects through two ligand-gated channels, **GABAA** and **GABAC** receptors, and a third receptor, **GABAB** (ref. 1), which acts through G proteins to regulate potassium and calcium channels. Cells heterologously expressing the cloned DNA encoding the **GABABR1** protein exhibit high-affinity antagonist-binding sites, but they produce little of the functional activity expected from studies of endogenous **GABAB** receptors in the brain. Here we describe a new member of the **GABAB** polypeptide family, **GABABR2**, that shows sequence homology to **GABABR1**. Neither **GABABR1** nor **GABABR2**, when expressed individually, activates GIRK-type potassium channels; however, the combination of **GABABR1** and **GABABR2** confers robust stimulation of channel activity. Both genes are co-expressed in individual neurons, and both proteins co-localize in transfected cells. Moreover, immunoprecipitation experiments indicate that the two polypeptides associate with each other, probably as **heterodimers**. Several G-protein-coupled receptors (GPCRs) exist as high-molecular-weight species, consistent with the formation of dimers by these receptors, but the relevance of these species for the functioning of GPCRs has not been established. We have now shown that co-expression of two GPCR structures, **GABABR1** and **GABABR2**, belonging to the same subfamily is essential for signal transduction by **GABAB** receptors.

=> s 19 and heteromer?

L18 16 L9 AND HETEROMER?

=> s 118 not 117

L19 14 L18 NOT L17

=> d his



FILE 'MEDLINE, BIOSIS, BIOTECHNO' ENTERED AT 16:10:41 ON 19 MAY 2000

L1 9581 S GABA? RECEPTOR  
 L2 536512 S HETERO?  
 L3 571 S L1 AND L2  
 L4 415 S L3 AND PY <1998  
 L5 10640 S COEXPRESSION  
 L6 8 S L4 AND L5  
 L7 7 DUP REM L6 (1 DUPLICATE REMOVED)  
 L8 3037 S GABAB  
 L9 3068 S GABAB?  
 L10 146 S L9 AND L2  
 L11 75555 S DIMER OR DIMERIC OR HETERODIMER OR HETERODIMERIC  
 L12 8 S L11 AND L9  
 L13 6 DUP REM L12 (2 DUPLICATES REMOVED)  
 L14 26750 S HETERODIMER?  
 L15 15 S L14 AND L9  
 L16 7 S L15 NOT L12  
 L17 6 DUP REM L16 (1 DUPLICATE REMOVED)  
 L18 16 S L9 AND HETEROMER?  
 L19 14 S L18 NOT L17

=> s l19 not l12

L20 13 L19 NOT L12

=> dup rem l20

PROCESSING COMPLETED FOR L20  
 L21 10 DUP REM L20 (3 DUPLICATES REMOVED)

=> d ibib abs 1-10

L21 ANSWER 1 OF 10 BIOSIS COPYRIGHT 2000 BIOSIS  
 ACCESSION NUMBER: 2000:153416 BIOSIS  
 DOCUMENT NUMBER: PREV200000153416  
 TITLE: Ca2+ requirement for high-affinity gamma-aminobutyric acid (GABA) binding at GABAB receptors: Involvement of serine 269 of the GABABR1 subunit.  
 AUTHOR(S): Galvez, Thierry (1); Urwyler, Stephan; Prezeau, Laurent; Mosbacher, Johannes; Joly, Cecile; Malitschek, Barbara; Heid, Jakob; Brabet, Isabelle; Froestl, Wolfgang; Bettler, Bernhard; Kaupmann, Klemens; Pin, Jean-Philippe  
 CORPORATE SOURCE: (1) Laboratoire des Mecanismes Moleculaires des Communications Cellulaires, CCIPE-Centre National de la Recherche Scientifique-UPR9023, 141 Rue de la Cardonville, F-34094, Montpellier Cedex 5 France  
 SOURCE: Molecular Pharmacology., (March, 2000) Vol. 57, No. 3, pp. 419-426.  
 ISSN: 0026-895X.  
 DOCUMENT TYPE: Article  
 LANGUAGE: English  
 SUMMARY LANGUAGE: English

AB The gamma-aminobutyric acid (GABA) receptor type B (GABABR) is constituted of at least two homologous proteins, GABABR1 and GABABR2. These proteins share sequence and structural similarity with metabotropic glutamate and Ca2+-sensing receptors, both of which are sensitive to Ca2+. Using rat brain membranes, we report here that the affinity of GABA and 3-aminopropylphosphinic acid for the GABABR receptor is decreased by a factor >10 in the absence of Ca2+. Such a large effect of Ca2+ is not observed with baclofen or the antagonists CGP64213 and CGP56999A. In contrast to baclofen, the potency of GABA in stimulating GTPgammaS binding in rat brain membranes is also decreased by a factor >10 upon Ca2+ removal. The potency for Ca2+ in regulating GABA affinity was 37

muM. In cells expressing GABABR1, the potency of GABA but not of baclofen, in displacing bound 125I-CGP64213 was similarly decreased in the absence of Ca<sup>2+</sup>. To identify residues that are responsible for the Ca<sup>2+</sup> effect, the pharmacological profile and the Ca<sup>2+</sup> sensitivity of a series of GABABR1 mutants were examined. The mutation of Ser269 into Ala was found to decrease the affinity of GABA, but not of baclofen, and the GABA affinity was found not to be affected upon Ca<sup>2+</sup> removal. Finally, the effect of Ca<sup>2+</sup> on the GABAB receptor function is no longer observed in cells coexpressing this GABABR1-S269A mutant and the wild-type GABABR2. Taken together, these results show that Ser269, which is conserved in the GABABR1 protein from *Caenorhabditis elegans* to mammals, is critical for the Ca<sup>2+</sup>-effect on the heteromeric GABAB receptor.

L21 ANSWER 2 OF 10 BIOSIS COPYRIGHT 2000 BIOSIS  
ACCESSION NUMBER: 2000:196949 BIOSIS  
DOCUMENT NUMBER: PREV200000196949  
TITLE: Distribution of the GABAB receptor subunit gb2 in rat CNS.  
AUTHOR(S): Clark, Janet A. (1); Mezey, Eva; Lam, Alan S.; Bonner, Tom I.  
CORPORATE SOURCE: (1) Laboratory of Genetics, National Institute of Mental Health, 36 Convent Drive, Bethesda, MD, 20892-4094 USA  
SOURCE: Brain Research, (March 31, 2000) Vol. 860, No. 1-2, pp. 41-52.  
ISSN: 0006-8993.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
AB We have identified and isolated human and rat cDNAs for a novel receptor, gb2, with 38% homology to the GABAB receptors gbl and gblb. These receptors comprise a new subfamily of seven transmembrane G protein-coupled receptors (GPCRs) that share structure and sequence similarities with the metabotropic glutamate receptors. In situ hybridization histochemistry using an antisense probe to this novel receptor mRNA shows a distribution in rat CNS nearly identical to that for the gbl receptor, although some regions showed significant differences. Specifically, message levels for gb2 were virtually absent in the caudate/putamen, and significantly lower in the medial basal hypothalamus, septum and brainstem as compared with gbl message levels. In contrast to gbl, gb2 mRNA was never detected in white matter suggesting that gb2 message is found exclusively in neurons. Finally, in rat brain regions showing significant overlap of message for gbl and gb2, the transcripts are often found in the same cells. Data from our previous work showing that coexpression of gb2 with gbl is necessary for expression of a functional receptor together with the detailed anatomical data presented here indicate that native GABAB receptors function as heteromeric proteins, the most abundant form being the gbl/gb2 receptor. However, the more limited distribution of gb2 receptor mRNA suggests that there are brain regions where GABAB receptors are composed of gbl and as yet unidentified family members.

L21 ANSWER 3 OF 10 BIOSIS COPYRIGHT 2000 BIOSIS  
ACCESSION NUMBER: 2000:146861 BIOSIS  
DOCUMENT NUMBER: PREV200000146861  
TITLE: Heteromeric GABAB receptors are activated by gamma-hydroxybutyrate.  
AUTHOR(S): Mosbacher, J. (1); Lingenhoebl, K. (1); Kaupmann, K. (1); Beck, P. (1); Pagano, A. (1); Brom, R. (1); Heid, J. (1); Ristig, D. (1); Meigel, I. (1); Schuler, V. (1); Klux, N. (1); Froestl, W. (1); Urwyler, S. (1); Bettler, B. (1)  
CORPORATE SOURCE: (1) Neuroscience Research, Novartis Pharma AG, 4002, Basel Switzerland  
SOURCE: Society for Neuroscience Abstracts., (1999) Vol. 25, No. 1-2, pp. 1480.  
Meeting Info.: 29th Annual Meeting of the Society for Neuroscience. Miami Beach, Florida, USA October 23-28,

Society for Neuroscience  
. ISSN: 0190-5295.

DOCUMENT TYPE: Conference  
LANGUAGE: English  
SUMMARY LANGUAGE: English

L21 ANSWER 4 OF 10 MEDLINE  
ACCESSION NUMBER: 2000040717 MEDLINE  
DOCUMENT NUMBER: 20040717  
TITLE: G-protein-coupled inwardly rectifying potassium channels are targets of alcohol action.

DUPLICATE 1

AUTHOR: Lewohl J M; Wilson W R; Mayfield R D; Brozowski S J; Morrisett R A; Harris R A  
CORPORATE SOURCE: Waggoner Center for Alcohol and Addiction Research and Section on Neurobiology, University of Texas at Austin, Austin, Texas 78712, USA.. lewohlj@mail.utexas.edu

CONTRACT NUMBER: AA06399 (NIAAA)  
AA03527 (NIAAA)  
GM47818 (NIGMS)

SOURCE: Nat Neurosci, {1999 Dec} 2 (12) 1084-90.  
Journal code: DA8. ISSN: 1097-6256.

PUB. COUNTRY: United States  
Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200003  
ENTRY WEEK: 20000304

AB G-protein-coupled inwardly rectifying potassium channels (GIRKs) are important for regulation of synaptic transmission and neuronal firing rates. Because of their key role in brain function, we asked if these potassium channels are targets of alcohol action. Ethanol enhanced function of cerebellar granule cell GIRKs coupled to **GABAB** receptors. Enhancement of GIRK function by ethanol was studied in detail using *Xenopus* oocytes expressing homomeric or **heteromeric** channels. Function of all GIRK channels was enhanced by intoxicating concentrations of ethanol, but other, related inwardly rectifying potassium channels were not affected. GIRK2/IRK1 chimeras and GIRK2 truncation mutants were used to identify a region of 43 amino acids in the carboxyl (C) terminus that is critical for the action of ethanol on these channels.

L21 ANSWER 5 OF 10 BIOSIS COPYRIGHT 2000 BIOSIS  
ACCESSION NUMBER: 2000:144595 BIOSIS  
DOCUMENT NUMBER: PREV200000144595  
TITLE: The **heteromeric GABAB** receptor recognizes G-protein alpha subunit C-termini.  
AUTHOR(S): Blahos, Jaroslav (1); Franek, Miloslav; Pagano, Adriana; Kaupmann, Klemens; Bettler, Bernhard; Pin, Jean-Philippe  
CORPORATE SOURCE: (1) CNRS UPR9023, Montpellier, 34094 France  
SOURCE: Society for Neuroscience Abstracts., (1999) Vol. 25, No. 1-2, pp. 967.

Meeting Info.: 29th Annual Meeting of the Society for Neuroscience. Miami Beach, Florida, USA October 23-28, 1999  
Society for Neuroscience  
. ISSN: 0190-5295.

DOCUMENT TYPE: Conference  
LANGUAGE: English  
SUMMARY LANGUAGE: English

L21 ANSWER 6 OF 10 MEDLINE  
ACCESSION NUMBER: 1999102694 MEDLINE  
DOCUMENT NUMBER: 99102694  
TITLE: Role of **heteromer** formation in **GABAB** receptor function [see comments].

DUPLICATE 2

COMMENT: Comment in: Science 1999 Jan 1;283(5398):14-5  
AUTHOR: Kuner R; Kohr G; Grunewald S; Eisenhardt G; Bach A; Kornau

CORPORATE SOURCE: H C BASF/BNX Bioscience AG, Department of Neuroscience, Im Neuenheimer Feld 515, D-69120 Heidelberg, Germany.  
 SOURCE: SCIENCE, (1999 Jan 1) 283 (5398) 74-7.  
 JOURNAL CODE: UJ7. ISSN: 0036-8075.  
 PUB. COUNTRY: United States  
 JOURNAL; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Cancer Journals; Priority Journals  
 OTHER SOURCE: GENBANK-AF109405  
 ENTRY MONTH: 199903  
 AB Recently, GBR1, a seven-transmembrane domain protein with high affinity for gamma-aminobutyric acid (GABA)B receptor antagonists, was identified. Here, a GBR1-related protein, GBR2, was shown to be coexpressed with GBR1 in many brain regions and to interact with it through a short domain in the carboxyl-terminal cytoplasmic tail. Heterologously expressed GBR2 mediated inhibition of adenylyl cyclase; however, inwardly rectifying potassium channels were activated by GABAB receptor agonists only upon coexpression with GBR1 and GBR2. Thus, the interaction of these receptors appears to be crucial for important physiological effects of GABA and provides a mechanism in receptor signaling pathways that involve a heterotrimeric GTP-binding protein.

I21 ANSWER 7 OF 10 MEDLINE DUPLICATE 3  
 ACCESSION NUMBER: 1999061981 MEDLINE  
 DOCUMENT NUMBER: 99061981  
 TITLE: Human gamma-aminobutyric acid type B receptors are differentially expressed and regulate inwardly rectifying K+ channels.  
 AUTHOR: Kaupmann K; Schuler V; Mosbacher J; Bischoff S; Bittiger H;  
 Heid J; Froestl W; Leonhard S; Pfaff T; Karschin A;  
 Bettler

B  
 CORPORATE SOURCE: Novartis Pharma AG, TA Nervous System, CH-4002 Basel, Switzerland.  
 SOURCE: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1998 Dec 8) 95 (25) 14991-6.  
 JOURNAL CODE: PV3. ISSN: 0027-8424.  
 PUB. COUNTRY: United States  
 JOURNAL; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals; Cancer Journals  
 OTHER SOURCE: GENBANK-AJ225028; GENBANK-AJ225029  
 ENTRY MONTH: 199903  
 AB gamma-Aminobutyric acid type B receptors (GABABRs) are involved in the fine tuning of inhibitory synaptic transmission. Presynaptic GABABRs inhibit neurotransmitter release by down-regulating high-voltage activated Ca2+ channels, whereas postsynaptic GABABRs decrease neuronal excitability by activating a prominent inwardly rectifying K+ (Kir) conductance that underlies the late inhibitory postsynaptic potentials. Here we report the cloning and functional characterization of two human GABABRs, hGABABR1a (hR1a) and hGABABR1b (hR1b). These receptors closely match the pharmacological properties and molecular weights of the most abundant native GABABRs. We show that in transfected mammalian cells hR1a and hR1b can modulate heteromeric Kir3.1/3.2 and Kir3.1/3.4 channels. Heterologous expression therefore supports the notion that Kir3 channels are the postsynaptic effectors of GABABRs. Our data further demonstrate that in principle either of the cloned receptors could mediate inhibitory postsynaptic potentials. We find that in the cerebellum hR1a and hR1b transcripts are largely confined to granule and Purkinje cells, respectively. This finding supports a selective association of hR1b, and not hR1a, with postsynaptic Kir3 channels. The mapping of the GABABR1 gene to human chromosome 6p21.3, in the vicinity of a susceptibility locus (EJM1) for idiopathic generalized epilepsies, identifies a candidate gene for inherited forms of epilepsy.

L21 ANSWER 8 OF 10 BIC COPYRIGHT 2000 BIOSIS  
 ACCESSION NUMBER: 1999077862 BIOSIS  
 DOCUMENT NUMBER: PREV199900317862  
 TITLE: **Heteromerization of GABAB receptors: A new principle for G protein-coupled receptors.** (Satellite Symposium to the 28th Annual Meeting of the Society for Neuroscience) (Los Angeles, California, USA; November 5-7, 1998).  
 AUTHOR(S): Kaupmann, Jkenebs; Bettler, Bernard (1)  
 CORPORATE SOURCE: (1) TA Nervous System, Novartis Pharma AG, CH-4002, Basel Switzerland  
 SOURCE: CNS Drug Reviews, (Winter, 1998) Vol. 4, No. 4, pp. 376-379.  
 ISSN: 1080-563X.  
 DOCUMENT TYPE: Conference  
 LANGUAGE: English

L21 ANSWER 9 OF 10 MEDLINE  
 ACCESSION NUMBER: 97338146 MEDLINE  
 DOCUMENT NUMBER: 97338146  
 TITLE: Activation of **heteromeric G** protein-gated inward rectifier K<sup>+</sup> channels overexpressed by adenovirus gene transfer inhibits the excitability of hippocampal neurons [published erratum appears in Proc Natl Acad Sci U S A

1997 Aug 19;94(17):9511].  
 AUTHOR: Ehrengruher M U; Dounnik C A; Xu Y; Garvey J; Jasek M C; Lester H A; Davidson N  
 CORPORATE SOURCE: Division of Biology, 156-29, California Institute of Technology, Pasadena, CA 91125, USA.  
 SOURCE: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1997 Jun 24) 94 (13) 7070-5.  
 Journal code: PV3. ISSN: 0027-8424.  
 PUB. COUNTRY: United States  
 LANGUAGE: English  
 FILE SEGMENT: Cancer Journals; Priority Journals  
 ENTRY MONTH: 199709

AB G protein-gated inward rectifier K<sup>+</sup> channel subunits 1-4 (GIRK1-4) have been cloned from neuronal and atrial tissue and function as heterotetramers. To examine the inhibition of neuronal excitation by GIRKs, we overexpressed GIRKs in cultured hippocampal neurons from 18 day rat embryos, which normally lack or show low amounts of GIRK protein and currents. Adenoviral recombinants containing the cDNAs for GIRK1, GIRK2, GIRK4, and the serotonin 1A receptor were constructed. Typical GIRK currents could be activated by endogenous **GABAB**, serotonin 5-HT1A, and adenosine A1 receptors in neurons coinfectd with GIRK1+2 or GIRK1+4. Under current clamp, GIRK activation increased the cell membrane conductance by 1- to 2-fold, hyperpolarized the cell by 11-14 mV, and inhibited action potential firing by increasing the threshold current for firing by 2- to 3-fold. These effects were not found in non- and mock-infected neurons, and were similar to the effects of muscarinic stimulation of native GIRK currents in atrial myocytes. Two inhibitory effects of GIRK activation, hyperpolarization and diminution of depolarizing pulses, were simulated from the experimental data. These inhibitory effects are physiologically important in the voltage range between the resting membrane potential and the potential where voltage-gated Na<sup>+</sup> and K<sup>+</sup> currents are activated; that is where GIRK currents are outward.

L21 ANSWER 10 OF 10 MEDLINE  
 ACCESSION NUMBER: 97040344 MEDLINE  
 DOCUMENT NUMBER: 97040344  
 TITLE: **GABAC receptors: relatively simple transmitter -gated ion channels?.**  
 AUTHOR: Johnston G A  
 CORPORATE SOURCE: Adrien Albert Laboratory of Medicinal Chemistry, Department of Pharmacology, University of Sydney, NSW, Australia.

SOURCE: TREND IN PHARMACOLOGICAL SCIENCES, 6 Sep) 17 (9)  
 319- Ref: 30  
 Journal code: WFT. ISSN: 0165-6147.  
 PUB. COUNTRY: ENGLAND: United Kingdom  
 Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LANGUAGE: English  
 ENTRY MONTH: 199702  
 ENTRY WEEK: 19970204  
 AB The inhibitory neurotransmitter, GABA, activates a variety of receptors  
 in

all areas of the CNS. Two major subtypes of GABA receptors are well known:

(1) GABAA receptors are ligand-gated Cl<sup>-</sup> channels that consist of a heteromeric mixture of protein subunits forming a pentameric structure, and (2) GABAB receptors couple to Ca<sup>2+</sup> and K<sup>+</sup> channels via G proteins and second messengers. Here, Graham Johnston discusses evidence for a third major subclass of GABA receptors. GABAC receptors appear to be relatively simple ligand-gated Cl<sup>-</sup> channels with a distinctive pharmacology, in that they are not blocked by bicuculline and not modulated by barbiturates, benzodiazepines or neuroactive steroids. Compared with GABAA receptors, GABAC receptors are activated at lower concentrations of GABA and are less liable to desensitization. In addition, their channels open for a longer time. The pharmacology of

these novel subtypes of GABA receptors may yield important therapeutic agents.

=> d his

(FILE 'HOME' ENTERED AT 16:10:24 ON 19 MAY 2000)

FILE 'MEDLINE, BIOSIS, BIOTECHNO' ENTERED AT 16:10:41 ON 19 MAY 2000

L1 9581 S GABA? RECEPTOR  
 L2 536512 S HETERO?  
 L3 571 S L1 AND L2  
 L4 415 S L3 AND PY <1998  
 L5 10640 S COEXPRESSION  
 L6 8 S L4 AND L5  
 L7 7 DUP REM L6 (1 DUPLICATE REMOVED)  
 L8 3037 S GABAB  
 L9 3068 S GABAB?  
 L10 146 S L9 AND L2  
 L11 75555 S DIMER OR DIMERIC OR HETERODIMER OR HETERODIMERIC  
 L12 8 S L11 AND L9  
 L13 6 DUP REM L12 (2 DUPLICATES REMOVED)  
 L14 26750 S HETERODIMER?  
 L15 15 S L14 AND L9  
 L16 7 S L15 NOT L12  
 L17 6 DUP REM L16 (1 DUPLICATE REMOVED)  
 L18 16 S L9 AND HETEROMER?  
 L19 14 S L18 NOT L17  
 L20 13 S L19 NOT L12  
 L21 10 DUP REM L20 (3 DUPLICATES REMOVED)

FILE 'HOME' ENTERED AT 14:04:44 ON 21 MAY 2000

=> file medline biosis biotechno

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.15

0.15

FILE 'MEDLINE' ENTERED AT 14:05:02 ON 21 MAY 2000

FILE 'BIOSIS' ENTERED AT 14:05:02 ON 21 MAY 2000

COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'BIOTECHNO' ENTERED AT 14:05:02 ON 21 MAY 2000

COPYRIGHT (C) 2000 Elsevier Science B.V., Amsterdam. All rights reserved.

=> s GABAB?

L1 3068 GABAB?

=> s gb2

L2 116 GB2

=> s l1 and l2

L3 4 L1 AND L2

=> dup rem l3

PROCESSING COMPLETED FOR L3

L4 3 DUP REM L3 (1 DUPLICATE REMOVED)

=> d ibib abs 1-3

L4 ANSWER 1 OF 3 BIOSIS COPYRIGHT 2000 BIOSIS

ACCESSION NUMBER: 2000:196949 BIOSIS

DOCUMENT NUMBER: PREV200000196949

TITLE: Distribution of the GABAB receptor subunit  
gb2, in rat CNS.

AUTHOR(S): Clark, Janet A. (1); Mezey, Eva; Lam, Alan S.; Bonner, Tom I.

CORPORATE SOURCE: (1) Laboratory of Genetics, National Institute of Mental Health, 36 Convent Drive, Bethesda, MD, 20892-4094 USA

SOURCE: Brain Research, (March 31, 2000) Vol. 860, No. 1-2, pp. 41-52.

ISSN: 0006-8993.

DOCUMENT TYPE: Article

LANGUAGE: English

SUMMARY LANGUAGE: English

AB We have identified and isolated human and rat cDNAs for a novel receptor, gb2, with 38% homology to the GABAB receptors gblA and gblB. These receptors comprise a new subfamily of seven transmembrane G protein-coupled receptors (GPCRs) that share structure and sequence similarities with the metabotropic glutamate receptors. In situ hybridization histochemistry using an antisense probe to this novel receptor mRNA shows a distribution in rat CNS nearly identical to that

for the gbl receptor, although some regions showed significant differences. Specifically, message levels for gb2 were virtually absent in the caudate/putamen, and significantly lower in the medial basal

In hypothalamus, septum and brainstem as compared with 1 message levels.

contrast to gbl, **gb2** mRNA was never detected in white matter suggesting that **gb2** message is found exclusively in neurons. Finally, in rat brain regions showing significant overlap of message for gbl and **gb2**, the transcripts are often found in the same cells. Data from our previous work showing that coexpression of **gb2** with gbl is necessary for expression of a functional receptor together with the detailed anatomical data presented here indicate that native **GABAB** receptors function as heteromeric proteins, the most abundant form being the gbl/**gb2** receptor. However, the more limited distribution of **gb2** receptor mRNA suggests that there are brain regions where **GABAB** receptors are composed of gbl and as yet unidentified family members.

L4 ANSWER 2 OF 3 MEDLINE DUPLICATE 1  
 ACCESSION NUMBER: 1999175124 MEDLINE  
 DOCUMENT NUMBER: 99175124  
 TITLE: Identification of a **GABAB** receptor subunit, **gb2**, required for functional **GABAB** receptor activity.  
 AUTHOR: Ng G Y; Clark J; Coulombe N; Ethier N; Hebert T E; Sullivan  
 R; Kargman S; Chateau-neuf A; Tsukamoto N; McDonald T; Whiting P; Mezey E; Johnson M P; Liu Q; Kolakowski L F Jr; Evans J F; Bonner T I; O'Neill G P  
 CORPORATE SOURCE: Merck Frosst Center for Therapeutic Research, Kirkland, Quebec H9H 3L1, Canada.. gordon\_ng@merck.com  
 SOURCE: JOURNAL OF BIOLOGICAL CHEMISTRY, (1999 Mar 19) 274 (12) 7607-10.  
 Journal code: HIV. ISSN: 0021-9258.  
 PUB. COUNTRY: United States  
 Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals; Cancer Journals  
 OTHER SOURCE: GENBANK-AF069755; GENBANK-AF056085; GENBANK-AF057085; GENBANK-AF095723; GENBANK-AF058795  
 ENTRY MONTH: 199906  
 ENTRY WEEK: 19990603

AB G protein-coupled receptors are commonly thought to bind their cognate ligands and elicit functional responses primarily as monomeric receptors. In studying the recombinant gamma-aminobutyric acid, type B (**GABAB**) receptor (gbla) and a **GABAB**-like orphan receptor (**gb2**), we observed that both receptors are functionally inactive when expressed individually in multiple heterologous systems. Characterization of the tissue distribution of each of the receptors by in situ hybridization histochemistry in rat brain revealed co-localization of gbl and **gb2** transcripts in many brain regions, suggesting the hypothesis that gbl and **gb2** may interact in vivo. In three established functional systems (inwardly rectifying K<sup>+</sup> channel currents in Xenopus oocytes, melanophore pigment aggregation, and direct cAMP measurements in HEK-293 cells), GABA mediated a functional response in cells coexpressing gbla and **gb2** but not in cells expressing either receptor individually. This GABA activity could be blocked with the **GABAB** receptor antagonist CGP71872. In COS-7 cells coexpressing gbla and **gb2** receptors, co-immunoprecipitation of gbla and **gb2** receptors was demonstrated, indicating that gbla and **gb2** act as subunits in the formation of a functional **GABAB** receptor.

L4 ANSWER 3 OF 3 BIOSIS COPYRIGHT 2000 BIOSIS  
 ACCESSION NUMBER: 1999:85564 BIOSIS  
 DOCUMENT NUMBER: PREV199900085564  
 TITLE: Functional expression and distribution of **GB2**, a second **GABAB** receptor.  
 AUTHOR(S): Clark, J. A.; Mezey, E.; Lam, A. S.; Bonner, T. I.  
 CORPORATE SOURCE: Sect. Genetics, NIMH, Bethesda, MD 20892-4094 USA



SOURCE:

Society for Neuroscience Abstracts, (1998) Vol. 24, No.  
1-2, pp. 1990.  
Meeting Info.: 28th Annual Meeting of the Society for  
Neuroscience, Part 2 Los Angeles, California, USA November  
7-12, 1998 Society for Neuroscience  
. ISSN: 0190-5295.  
Conference  
English

DOCUMENT TYPE:

LANGUAGE:

=> file medline biosis biotechno

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY

SESSION

0.15

0.15

FILE 'MEDLINE' ENTERED AT 16:10:41 ON 19 MAY 2000

FILE 'BIOSIS' ENTERED AT 16:10:41 ON 19 MAY 2000

COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'BIOTECHNO' ENTERED AT 16:10:41 ON 19 MAY 2000

COPYRIGHT (C) 2000 Elsevier Science B.V., Amsterdam. All rights reserved.

=> s gaba? receptor

L1 9581 GABA? RECEPTOR

=> s hetero?

L2 536512 HETERO?

=> s l1 and l2

L3 571 L1 AND L2

=> s l3 py <1998

MISSING OPERATOR L3 PY

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s l3 py<1998

MISSING OPERATOR L3 PY<1998

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s l1 py<1998

MISSING OPERATOR L1 PY<1998

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s l1 py <1998

MISSING OPERATOR L1 PY

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s l1 and py <1998

<-----User Break----->

u

SEARCH ENDED BY USER

=> s l3 and py <1998

2 FILES SEARCHED...

L4 415 L3 AND PY <1998

=> s coexpression

**WEST**☐ **Generate Collection**

L14: Entry 3 of 3

File: DWPI

Aug 12, 1999

DERWENT-ACC-NO: 1999-527300

DERWENT-WEEK: 199944

COPYRIGHT 2000 DERWENT INFORMATION LTD

TITLE: New DNA encoding human and murine receptor subunits, useful for identifying agonists and antagonists for treatment of depression, epilepsy and neuropsychiatric disorders

INVENTOR: BONNER, T I; BONNERT, T P; CLARK, J; KOLAKOWSKI, L F; LIU, Q; MCDONALD, T; NG, G Y K

## PATENT-ASSIGNEE:

ASSIGNEE	CODE
MERCK & CO INC	MERI
MERCK FROSST CANADA INC	MERI
UNIV TEXAS HEALTH SCI CENT SAN ANTONI	UYTEN
US NAT INST OF HEALTH CENT SAN ANTONI	USSH

## PRIORITY-DATA:

1998US-0073767

February 5, 1998

## PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9940114 A1	August 12, 1999	E	128	C07K014/705

DESIGNATED-STATES: CA JP US AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

## APPLICATION-DATA:

PUB-NO	APPL-DESCRIPTOR	APPL-NO	APPL-NO
WO 9940114A1	February 3, 1999	1999WO-US02361	N/A

INT-CL (IPC): C07K 14/705; C12N 5/10; C12N 15/09; C12N 15/11; C12N 15/12; C12N 15/62; G01N 33/566

ABSTRACTED-PUB-NO: WO 9940114A

## BASIC-ABSTRACT:

NOVELTY - DNA encoding human and murine GABAB (metabotropic lambda -amino-butyric acid) receptor subunit proteins HG20 and GABABR1a respectively, are new.

DETAILED DESCRIPTION - HG20 has an amino acid sequence selected from amino acid 9, 35, 36, 38, 39, 42, 44, 46, 52 or 57 to amino acid 941 of a fully defined amino acid sequence, and GABABR1a has a fully defined 960 amino acid sequence, both given in the specification.

INDEPENDENT CLAIMS are included for the following:

(1) isolated DNA (I) encoding HG20 comprising an amino acid sequence selected from residues 9-941, 35-941, 36-941, 38-941, 39-941, 42-941, 44-941, 46-941, 52-941 or 57-941 of the 941 amino acid sequence (I) given in the specification;

(2) an isolated DNA that hybridizes to HG20 DNA;

(3) an expression vector comprising HG20 DNA;

(4) a recombinant host cell comprising the vector;

(5) a protein (II) substantially free from other proteins, comprising HG20 having an amino acid sequence selected from residues 9-941, 35-941, 36-941, 38-941, 39-941, 42-941, 44-941, 46-941, 52-941 or 57-941 of (I) and optionally comprising a G-protein coupled receptor protein;

(6) a polypeptide (III) comprising a coiled-coil domain from the C-terminus of a GABAB receptor subunit and no other contiguous amino acid sequences longer than 5 amino acids from the same subunit, which mediates heterodimerization of the subunit with another GABAB receptor subunit;

(7) isolated DNA (IV) encoding GABABR1a having the sequence given in the specification;

(8) a protein, substantially free from other proteins, comprising a GABABR1a protein;

(9) identifying compounds (potential agonists or antagonists) which bind GABAB receptors, comprising:

(a) culturing recombinant cells containing vectors encoding HG20 and GABABR1a or GABABR1b;

(b) allowing the expressed HG20 to form heterodimers with expressed GABABR1a or GABABR1b;

(c) adding a labeled GABAB receptor ligand in the presence and absence of the test compound; and

(d) measuring the binding of the ligand to the heterodimers, where the compound is a potential agonist/antagonist when the amount of ligand binding is less in the presence of, than in the absence of the test compound;

(10) identifying HG20 agonists and antagonists, comprising:

(a) exposing cells containing expression vectors encoding HG20, and GABABR1a or GABABR1b, to a candidate GABAB receptor agonist; and

(b) measuring the functional response of the cells and comparing to controls;

(11) producing functional GABAB receptors in cells, comprising transfecting with 2 expression vectors which express HG20, and GABABR1a or GABABR1b, allowing heterodimers between HG20 and GABABR1a or GABABR1b;

(12) an antibody specific to HG20;

(13) preparation of truncated HG20; and

(14) a chimeric HG20 protein having HG20 covalently linked at the N-terminus to non-HG20 amino acid sequence.

ACTIVITY - Antidepressant; anticonvulsant; nootropic; anxiolytics; antispasmodic; relaxant.

## MECHANISM OF ACTION - Inhibitors

USE - Cells expressing the new receptor subunits are useful for identifying GABAB receptor agonists and antagonists (claimed). HG20 proteins and their antagonists are useful for inhibiting HG20 or GABAB receptor function, useful for treating depression, epilepsy, neuropsychiatric disorders, dementias, muscular contractions, and CNS disorders. Agonists are useful for treating asthma, muscular contractions, epilepsy, neuropsychiatric disorders, dementias and muscle disorders.

CHOSEN-DRAWING: Dwg.0/27

TITLE-TERMS: NEW DNA ENCODE HUMAN MURINE RECEPTOR USEFUL IDENTIFY AGONIST  
ANTAGONIST TREAT DEPRESS EPILEPSY DISORDER

DERWENT-CLASS: B04 D16 S03

CPI-CODES: B04-E02D; B04-E03D; B04-E08; B04-F0100E; B04-F1100E; B04-G04;  
B04-K01K; B14-J01A1; B14-J01A4; B14-J05A; B14-J07; B14-K01A; B14-L01; B14-L06;  
B14-S03; D05-H08; D05-H09; D05-H11; D05-H12A; D05-H12E; D05-H14; D05-H17A4;  
D05-H17C;

EPI-CODES: S03-E14H4;

## CHEMICAL-CODES:

Chemical Indexing M1 \*01\*

Fragmentation Code

M423 M710 M905 N135 P431 P444 P446 P517 P822 P831

Q233

Specific Compounds

A00NST A00NSN

Chemical Indexing M1 \*02\*

Fragmentation Code

M423 M710 M905 N135 P431 P444 P446 P517 P822 P831

Q233

Specific Compounds

A00GTT A00GTN

Chemical Indexing M1 \*03\*

Fragmentation Code

M423 M710 M905 N135 P431 P444 P446 P517 P822 P831

Q233

Specific Compounds

A00H3T A00H3N

## SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1999-154834

Non-CPI Secondary Accession Numbers: N1999-390599

**WEST**☐ Generate Collection

L20: Entry 7 of 10

File: DWPI

Oct 14, 1999

DERWENT-ACC-NO: 1999-610994  
DERWENT-WEEK: 199952  
COPYRIGHT 2000 DERWENT INFORMATION LTD

TITLE: Novel nucleic acids, used to screen for specific modulators, e.g. for treating spasticity or Alzheimer's disease

INVENTOR: BUSBY, J G; GARRETT, J E; SIMIN, R T; STORMANN, T M

PATENT-ASSIGNEE:

ASSIGNEE  
NPS PHARM INC

CODE  
NPSPN

PRIORITY-DATA:  
1998US-0080676

April 3, 1998

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9951636 A2	October 14, 1999	E	077	C07K014/47

DESIGNATED-STATES: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES  
FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD  
MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN  
YU ZA ZW AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA  
PT SD SE SL SZ UG ZW

APPLICATION-DATA:

PUB-NO	APPL-DESCRIPTOR	APPL-NO	APPL-NO
WO 9951636A2	April 2, 1999	1999WO-US07352	N/A

INT-CL (IPC): A01K 67/027; C07K 14/47; C07K 16/28; C12N 5/06; C12N 15/12

ABSTRACTED-PUB-NO: WO 9951636A  
BASIC-ABSTRACT:

NOVELTY - Purified nucleic acid (I) contains at least 18 contiguous nucleotides (nt) from a fully defined 2823 bp sequence given in the specification.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (a) expression vector containing (I);
- (b) recombinant cells containing this vector;
- (c) nucleic acid (Ia) of 20 nt, of which at least 18 are complementary to (I) or its perfect complement;
- (d) purified polypeptides (II) containing at least 6 amino acids (aa) from a

fully defined 943 residue aa sequence given in the specification, representing the human gamma -aminobutyric acid receptor GABABR2;

- (e) binding agent (III) specific for (II);
- (f) recombinant production of (II), or its fragments, by culturing cells of (b);
- (g) method for identifying modulators of (II) activity;
- (h) co-expression system comprising, in a cell, at least one of GABABR1a or R1b, GABABR2 and Gq05;
- (i) screening for compounds that act on GABABR1a, R1b or R2, using the system of (h); and
- (j) transgenic non-human animals containing (I).

ACTIVITY - Antispastic; antineurodegeneration; analgesic; anti-addictive; cardiovascular.

MECHANISM OF ACTION - (II) modulate synaptic transmissions by inhibiting presynaptic transmitter release and by increasing potassium ion conductance (resulting in long-lasting inhibition of postsynaptic potentials).

USE - (I) are used

- (1) for recombinant production of polypeptides (II), i.e. the human gamma -aminobutyric acid receptor GABABR2;
- (2) as nucleic acid probes and primers for detecting (II)-encoding nucleic acid or similar sequences;
- (3) to create transgenic animals;
- (4) to identify antisense or related agents; and
- (5) to express chimeric receptors.

(II) are used (i) to raise specific antibodies (Ab) and (ii) to identify specific modulators of GABABR2. These modulators are potentially useful for treating e.g. spasticity, motor control disorders, Alzheimer's or Huntington's diseases, pain, cognitive disorders, alcohol addiction (or withdrawal), feeding behavior, cardiovascular or respiratory disorders. Ab are used as therapeutic modulators; diagnostically for quantifying GABABR2, for affinity purification and for studying synthesis, structure and function of the receptor. Transgenic animals are useful for in vivo studies on the effects of GABABR2 and of agents that mimic or block this receptor.

CHOSEN-DRAWING: Dwg.0/4

TITLE-TERMS: NOVEL NUCLEIC ACID SCREEN SPECIFIC MODULATE TREAT SPASTICITY DISEASE

DERWENT-CLASS: B04 D16 F14

CPI-CODES: B04-C01; B04-E03D; B04-E05; B04-E06; B04-E08; B04-F0100E; B04-G04; B04-K01; B04-N04; B04-P0100E; B11-C08E; B12-K04E; B12-K04F; B14-C01; B14-F01; B14-F02; B14-J01A4; B14-J02; B14-J02B; B14-M01; B14-M01A; B14-M01C; D05-H08; D05-H09; D05-H12A; D05-H12E; D05-H14; D05-H16A; D05-H17A4;

CHEMICAL-CODES:

Chemical Indexing M1 \*01\*  
Fragmentation Code

M423 M710 M750 M781 M905 N102 P411 P446 P510 P520  
P522 P625 P641 P642 P646 P820 P831 Q233 Q505  
Specific Compounds  
A00H3T A00H3A A00H3D A00H3N

Chemical Indexing M1 \*02\*  
Fragmentation Code  
M423 M710 M750 M781 M905 N102 P411 P446 P510 P520  
P522 P625 P641 P642 P646 P820 P831 Q233 Q505  
Specific Compounds  
A00H1T A00H1A A00H1D A00H1N

Chemical Indexing M1 \*03\*  
Fragmentation Code  
M423 M710 M750 M781 M905 N102 P831 Q233 Q505  
Specific Compounds  
A00NSA A00NSD A00NSN

Chemical Indexing M1 \*04\*  
Fragmentation Code  
M423 M710 M750 M781 M905 N102 P831 Q233 Q505  
Specific Compounds  
A012PA A012PD A012PN

Chemical Indexing M1 \*05\*  
Fragmentation Code  
M423 M710 M905 P831 Q233  
Specific Compounds  
A00GTN

Chemical Indexing M1 \*06\*  
Fragmentation Code  
M423 M710 M905 Q233  
Specific Compounds  
A00C8N

Chemical Indexing M6 \*07\*  
Fragmentation Code  
M905 P411 P446 P510 P520 P522 P625 P820 P831 Q233  
Q505 R515 R521 R627 R633 R637 R639

## SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1999-177900

Non-CPI Secondary Accession Numbers: N1999-450204



**WEST****Freeform Search**

Database:

US Patents Full-Text Database  
JPO Abstracts Database  
EPO Abstracts Database  
Derwent World Patents Index  
IBM Technical Disclosure Bulletins

Term:

gababr2

Display:  Documents in Display Format:  Starting with Number Generate: ☐ Hit List ☒ Hit Count ☐ Image

Search

Clear

Help

Logout

Interrupt

Main Menu

Show S Numbers

Edit S Numbers

Preferences

---

**Search History**

---

Today's Date: 5/21/2000

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,JPAB,EPAB,DWPI	gababr2	2	<a href="#">L21</a>
USPT,JPAB,EPAB,DWPI	118 same 112	10	<a href="#">L20</a>
USPT,JPAB,EPAB,DWPI	118 and 112	53	<a href="#">L19</a>
USPT,JPAB,EPAB,DWPI	co-express\$	1317	<a href="#">L18</a>
USPT,JPAB,EPAB,DWPI	116 same 112	8	<a href="#">L17</a>
USPT,JPAB,EPAB,DWPI	dimer\$	53491	<a href="#">L16</a>
USPT,JPAB,EPAB,DWPI	gb2 same 113	0	<a href="#">L15</a>
USPT,JPAB,EPAB,DWPI,TDBD	112 same 113	3	<a href="#">L14</a>
USPT,JPAB,EPAB,DWPI,TDBD	12 or 14	2946	<a href="#">L13</a>
USPT,JPAB,EPAB,DWPI,TDBD	GABA\$	4344	<a href="#">L12</a>
USPT,JPAB,EPAB,DWPI	11 and 110	2	<a href="#">L11</a>
USPT,JPAB,EPAB,DWPI	gb2	47050	<a href="#">L10</a>
USPT	gababr\$	0	<a href="#">L9</a>
USPT	gababr2	0	<a href="#">L8</a>
USPT	gabab	5	<a href="#">L7</a>
USPT	gabab\$	7	<a href="#">L6</a>
USPT,JPAB,EPAB,DWPI,TDBD	s 14 and 11	0	<a href="#">L5</a>
USPT,JPAB,EPAB,DWPI,TDBD	heterodimer\$	2746	<a href="#">L4</a>
USPT,JPAB,EPAB,DWPI,TDBD	11 and 12	0	<a href="#">L3</a>
USPT,JPAB,EPAB,DWPI,TDBD	heteromer\$	275	<a href="#">L2</a>
USPT,JPAB,EPAB,DWPI,TDBD	GABAB\$	54	<a href="#">L1</a>